MCID: MLN064
MIFTS: 26

Melanoma of Soft Tissue malady

Categories: Rare diseases, Skin diseases, Muscle diseases, Cancer diseases

Aliases & Classifications for Melanoma of Soft Tissue

Aliases & Descriptions for Melanoma of Soft Tissue:

Name: Melanoma of Soft Tissue 56
Clear Cell Sarcoma of the Tendons and Aponeuroses 56

Classifications:



External Ids:

Orphanet 56 ORPHA97338

Summaries for Melanoma of Soft Tissue

MalaCards based summary : Melanoma of Soft Tissue, also known as clear cell sarcoma of the tendons and aponeuroses, is related to clear cell sarcoma and melanoma. An important gene associated with Melanoma of Soft Tissue is ATF1 (Activating Transcription Factor 1), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and HTLV-I infection. The drugs Cyclophosphamide and Morphine have been mentioned in the context of this disorder.

Wikipedia : 71 Clear-cell sarcoma (formerly known as malignant melanoma of the soft parts) is a rare form of cancer... more...

Related Diseases for Melanoma of Soft Tissue

Diseases related to Melanoma of Soft Tissue via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
id Related Disease Score Top Affiliating Genes
1 clear cell sarcoma 11.4
2 melanoma 10.0
3 hypohidrosis 9.9 ATF1 EWSR1
4 sarcoma 9.9
5 stickler syndrome, type i 9.9 ATF1 EWSR1
6 morbid obesity 9.8 ATF1 CREB1
7 hurst hallam hockey syndrome 9.8 ATF1 CREB1
8 kala-azar 1 9.8 ATF1 EWSR1
9 bilateral multicystic dysplastic kidney 9.7 ATF1 CREB1 EWSR1
10 coronary restenosis 9.7 ATF1 CREB1 EWSR1
11 juvenile xanthogranuloma 9.7 ATF1 CREB1 EWSR1
12 pulmonary immaturity 9.6 ATF1 CREB1 EWSR1

Graphical network of the top 20 diseases related to Melanoma of Soft Tissue:



Diseases related to Melanoma of Soft Tissue

Symptoms & Phenotypes for Melanoma of Soft Tissue

Drugs & Therapeutics for Melanoma of Soft Tissue

Drugs for Melanoma of Soft Tissue (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
2
Morphine Approved, Investigational Phase 3 57-27-2 5288826
3
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5 Liver Extracts Phase 3,Phase 1,Phase 2,Early Phase 1
6 pancreatic polypeptide Phase 3
7 Interleukin-2 Phase 3,Phase 2,Phase 1
8 Epoetin alfa Phase 3 113427-24-0
9 Analgesics Phase 3,Phase 2,Phase 1
10 Adjuvants, Anesthesia Phase 3
11 Narcotics Phase 3
12 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
13 Analgesics, Opioid Phase 3
14 Anesthetics Phase 3,Phase 2
15 Vaccines Phase 3,Phase 1,Phase 2
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 3
20 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1
21
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
22
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
23
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
24
Lorazepam Approved Phase 2 846-49-1 3958
25
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
26
Dactinomycin Approved Phase 2 50-76-0 2019 457193
27
Acetaminophen Approved Phase 2,Phase 1 103-90-2 1983
28
Diphenhydramine Approved Phase 2,Phase 1 58-73-1, 147-24-0 3100
29
Promethazine Approved Phase 2,Phase 1 60-87-7 4927
30
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
31
Dabrafenib Approved Phase 1, Phase 2 44462760 44516822
32
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
33
Trametinib Approved Phase 1, Phase 2 871700-17-3 11707110
34
nivolumab Approved Phase 1, Phase 2 946414-94-4
35
Trabectedin Approved, Investigational Phase 1, Phase 2 114899-77-3 108150
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
37
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
38
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
39
Propranolol Approved, Investigational Phase 1, Phase 2 525-66-6 4946
40
Doxil Approved June 1999 Phase 1, Phase 2 31703
41 Alkylating Agents Phase 2,Phase 1
42 Immunosuppressive Agents Phase 2,Phase 1
43 Antineoplastic Agents, Alkylating Phase 2,Phase 1
44
Iodine Phase 2,Phase 1 7553-56-2 807
45 cadexomer iodine Phase 2,Phase 1
46 Albumin-Bound Paclitaxel Phase 1, Phase 2
47 Topoisomerase Inhibitors Phase 1, Phase 2
48 Nucleic Acid Synthesis Inhibitors Phase 2
49 Anti-Bacterial Agents Phase 2,Phase 1
50 Immunoglobulins Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 107)
id Name Status NCT ID Phase
1 Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases Completed NCT00540969 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
4 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
5 Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Active, not recruiting NCT01223248 Phase 3
6 M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma Not yet recruiting NCT00477906 Phase 3
7 Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases Completed NCT00204581 Phase 2
8 Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery Completed NCT00004250 Phase 2
9 A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 Completed NCT01480323 Phase 2
10 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma Completed NCT00003308 Phase 2
11 Intratumoral Application of L19IL2 in Patients With Malignant Melanoma Completed NCT01253096 Phase 2
12 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
13 Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Completed NCT00041808 Phase 1, Phase 2
14 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
15 Radiotherapy & Combi in Metastatic Melanoma Recruiting NCT02392871 Phase 1, Phase 2
16 Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Recruiting NCT03138161 Phase 1, Phase 2
17 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
18 Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy Recruiting NCT02968303 Phase 2
19 A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Recruiting NCT02452424 Phase 1, Phase 2
20 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2
21 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2
22 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Recruiting NCT02304458 Phase 1, Phase 2
23 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Recruiting NCT01586767 Phase 2
24 Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer Active, not recruiting NCT02274779 Phase 2
25 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
26 A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping Active, not recruiting NCT02509598 Phase 2
27 A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Active, not recruiting NCT02722798 Phase 2
28 Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Active, not recruiting NCT02304367 Phase 2
29 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Tria Not yet recruiting NCT02732678 Phase 1, Phase 2
30 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma Terminated NCT00123786 Phase 2
31 Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain Terminated NCT00550654 Phase 2
32 HYPAZ: Hypertension Induced by Pazopanib Terminated NCT01392352 Phase 2
33 SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) Withdrawn NCT02342600 Phase 2
34 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer Withdrawn NCT01065441 Phase 1, Phase 2
35 A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer Unknown status NCT02015416 Phase 1
36 Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Completed NCT00580320 Phase 1
37 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Completed NCT00703625 Phase 1
38 Vaccine Therapy in Treating Patients With Metastatic Cancer Completed NCT00020267 Phase 1
39 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Completed NCT00703170 Phase 1
40 Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Completed NCT00003750 Phase 1
41 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
42 Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum Completed NCT01313429 Phase 1
43 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
44 Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity Completed NCT00001577 Phase 1
45 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
46 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
47 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
48 High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer Completed NCT00002854 Phase 1
49 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1
50 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1

Search NIH Clinical Center for Melanoma of Soft Tissue

Genetic Tests for Melanoma of Soft Tissue

Anatomical Context for Melanoma of Soft Tissue

Publications for Melanoma of Soft Tissue

Articles related to Melanoma of Soft Tissue:

id Title Authors Year
1
Lessons to be learned: a case study approach. Malignant melanoma of soft tissue. ( 15712852 )
2005
2
Malignant melanoma of soft tissues (clear cell sarcoma) of the foot. Is MRI able to perform a specific diagnosis? Report of one case and review of the radiological literature. ( 11268490 )
2000
3
Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft tissue). A case report. ( 2149419 )
1990
4
Clear cell sarcoma of tendons and aponeuroses: malignant melanoma of soft tissues? Report of four cases. ( 556273 )
1979

Variations for Melanoma of Soft Tissue

Expression for Melanoma of Soft Tissue

Search GEO for disease gene expression data for Melanoma of Soft Tissue.

Pathways for Melanoma of Soft Tissue

GO Terms for Melanoma of Soft Tissue

Cellular components related to Melanoma of Soft Tissue according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.62 ATF1 CREB1

Molecular functions related to Melanoma of Soft Tissue according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 8.62 ATF1 CREB1

Sources for Melanoma of Soft Tissue

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....